Multistage investment, systematic risk premium and CAPM beta: empirical evidence from product development

Zaur Rzakhanov

Applied Financial Economics, 2012, vol. 22, issue 10, 777-790

Abstract: Recent theoretical literature suggests that the magnitude of the systematic risk premium for a multistage investment project is subject to various forces that may cause the premium to change across stages. To test this hypothesis, I investigate whether Capital Asset Pricing Model (CAPM) beta differs by product development stage in the biotechnology industry. To this end I estimate CAPM beta for various stages of drug development using Full-Information Beta (FIB) technique. Findings indicate that early stage drug development projects have higher CAPM beta than drugs in later stages of development or in production and marketing. The beta appears to decrease monotonically as a project approaches completion.

Date: 2012
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1080/09603107.2011.627209 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:taf:apfiec:v:22:y:2012:i:10:p:777-790

Ordering information: This journal article can be ordered from
http://www.tandfonline.com/pricing/journal/RAFE20

DOI: 10.1080/09603107.2011.627209

Access Statistics for this article

Applied Financial Economics is currently edited by Anita Phillips

More articles in Applied Financial Economics from Taylor & Francis Journals
Bibliographic data for series maintained by Chris Longhurst ().